Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (301-310 of 578) with videos related to

Pageof 58
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive RelapseIgnace Vergote, Deborah Armstrong, Giovanni Scambia, et al.
American Journal of Obstetrics and Gynecology|March 29, 2025
Presence of atypical extravillous trophoblast foci is an independent predictor of the risk of progression to postmolar neoplasiaSophie Schoenen, Katty Delbecque, Etienne Marbaix, et al.
Archives of Gynecology and Obstetrics|October 16, 2014
Surgical and systemic management of endometrial cancer: an international surveyChristina Fotopoulou, Robert Kraetschell, Sean Dowdy, et al.
Gynecologic Oncology|December 5, 2025
First experience with intraperitoneal <sup>224</sup>Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancerYun Wang, Els Van Nieuwenhuysen, Mona-Elisabeth Revheim, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 4, 2026
Impact of atypical extra-villous trophoblast foci on the natural history and management of post-molar gestational trophoblastic neoplasiaSophie Schoenen, Katty Delbecque, Etienne Marbaix, et al.
Frontiers in Oncology|September 26, 2019
Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 ConsortiumIsabelle Ray-Coquard, Ioana Braicu, Regina Berger, et al.
Molecular Cancer|September 18, 2012
Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortiumStefanie Aust, Anna Bachmayr-Heyda, Petra Pateisky, et al.
Journal of Ovarian Research|July 2, 2013
Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortiumFabian Trillsch, Linn Woelber, Christine Eulenburg, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2015
Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancerSandrina Lambrechts, Dominiek Smeets, Matthieu Moisse, et al.
Targeted Oncology|August 12, 2017
A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric CancersBernard Escudier, Sandrine Faivre, Eric Van Cutsem, et al.
Pageof 58

Showing results (301-310 of 578) with videos related to

Sort By:
Pageof 58
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive RelapseIgnace Vergote, Deborah Armstrong, Giovanni Scambia, et al.
American Journal of Obstetrics and Gynecology|March 29, 2025
Presence of atypical extravillous trophoblast foci is an independent predictor of the risk of progression to postmolar neoplasiaSophie Schoenen, Katty Delbecque, Etienne Marbaix, et al.
Archives of Gynecology and Obstetrics|October 16, 2014
Surgical and systemic management of endometrial cancer: an international surveyChristina Fotopoulou, Robert Kraetschell, Sean Dowdy, et al.
Gynecologic Oncology|December 5, 2025
First experience with intraperitoneal <sup>224</sup>Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancerYun Wang, Els Van Nieuwenhuysen, Mona-Elisabeth Revheim, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 4, 2026
Impact of atypical extra-villous trophoblast foci on the natural history and management of post-molar gestational trophoblastic neoplasiaSophie Schoenen, Katty Delbecque, Etienne Marbaix, et al.
Frontiers in Oncology|September 26, 2019
Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 ConsortiumIsabelle Ray-Coquard, Ioana Braicu, Regina Berger, et al.
Molecular Cancer|September 18, 2012
Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortiumStefanie Aust, Anna Bachmayr-Heyda, Petra Pateisky, et al.
Journal of Ovarian Research|July 2, 2013
Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortiumFabian Trillsch, Linn Woelber, Christine Eulenburg, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2015
Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancerSandrina Lambrechts, Dominiek Smeets, Matthieu Moisse, et al.
Targeted Oncology|August 12, 2017
A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric CancersBernard Escudier, Sandrine Faivre, Eric Van Cutsem, et al.
Pageof 58